JPMorgan upgraded IGM Biosciences (IGMS) to Neutral from Underweight without a price target The firm says that with the company announcing discontinuation of imvotamab development alongside a pause of its clinical stage IgM assets, it sees its Underweight thesis “now borne out.” Given the uncertain path forward for IGM, JPMorgan no longer ascribes pipeline value in its updated model for shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
- IGM Biosciences Halts Antibody Therapies, Cuts Workforce
- IGM Biosciences downgraded to Hold from Buy at Jefferies
- AMD downgraded, Nike upgraded: Wall Street’s top analyst calls
- IGM Biosciences price target lowered to $2 from $12 at Truist
- Morning Movers: Constellation Energy climbs following deal to buy Calpine